Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

This is a randomized, single-center phase 3 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome. It has acceptable side effects, good clinical availability, and is cost-effective. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of Iguratimod in the treatment of chronic GVHD.

NCT Number	NCT06244628
Lead Sponsor	Xuzhou Medical University
Conditions	cGVHD
Enrollment	20 participants
Start Date	2024-01-10
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-27